Physician profile
William Ward
NPI 1689657785
$2,241.42
in general payments reported to CMS, 2019-2025
19 companies · $71.99 in 2025
The $71.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $242 · 2021: $598 · 2022: $829 · 2023: $230 · 2024: $47.98 · 2025: $71.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.28 | 2019-2023 | Stiolto Respimat, Jardiance, Spiriva Respimat |
| Abbvie INC. | $370.97 | 2021-2023 | Viberzi, Linzess, Vraylar |
| Glaxosmithkline, LLC. | $274.42 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.83 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $197.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $127.39 | 2021 | |
| Pfizer INC. | $112.68 | 2019-2023 | |
| Novo Nordisk INC | $109.65 | 2022-2025 | Ozempic, Rybelsus |
| Organogenesis INC. | $101.94 | 2021-2023 | Puraply |
| Gilead Sciences, INC. | $81.80 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $76.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $44.32 | 2023-2024 | Gardasil 9, Proquad, Gardasil |
| Allergan, INC. | $27.77 | 2020 | |
| Lilly USA, LLC | $23.49 | 2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.48 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.03 | 2023 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $14.86 | 2021 | |
| Axsome Therapeutics, INC. | $14.83 | 2023 | Auvelity |
| Astellas Pharma US INC | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.